secwatch.observer — SEC 8-K summary
======================================

Issuer:     LABCORP HOLDINGS INC. (LH)
CIK:        0000920148
Form:       8-K
Filed at:   2025-02-06T23:59:59+00:00
Accession:  0000920148-25-000021
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Labcorp Q4 revenue $3.33B (+9.8% YoY); adj. EPS $3.45; FY2025 rev. midpoint ~$14.0B, adj. EPS $16.00
--------------------------------------------------------------------------------

- Q4 revenue $3.33B (+9.8% YoY); diluted EPS $1.70 vs ($1.95); adjusted EPS $3.45 vs $3.30; free cash flow $665.1M vs $412.4M.
- Full year 2024 revenue $13.01B (+7.0%); diluted EPS $8.84 vs $4.33; adjusted EPS $14.57 vs $13.56; free cash flow $1.10B vs $748.7M.
- Diagnostics Labs segment Q4 revenue $2.59B (+10.2%); Biopharma Lab Services revenue $767.0M (+10.4%).
- FY2025 guidance: revenue $13.88B-$14.05B (midpoint +7.4%), adjusted EPS $15.60-$16.40 (midpoint +9.8%), free cash flow $1.10B-$1.25B.
- Board declared $0.72 quarterly dividend payable March 12, 2025; $839M spent on acquisitions in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/920148/000092014825000021/0000920148-25-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/920148/000092014825000021/lh-20250206.htm
  HTML page:      https://secwatch.observer/filing/0000920148-25-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer